

Biography



Michelle Gon

Partner

McDermott Will & Emery

Tel: +86 21 6105 0999

Fax: +86 21 6105 0501

michellegon@mwechinalaw.com

Practice Areas & Industries

- Antitrust & Competition
- Compliance
- Corporate
- Corporate Responsibility and Governance
- Health and Life Sciences
- Mergers & Acquisitions
- White-Collar & Securities Defense
- Franchise

Languages

- English
- Mandarin
- Taiwanese

Education

- US Case Western Reserve University, JD, 1985
- University of Illinois Urbana-Champaign, MCL, 1982
- National Taiwan University, LLB, 1976

Michelle Gon is a partner of McDermott Will & Emery. She is stationed at the firm's strategic alliance office, MWE China Law Offices, in Shanghai. Her practice focuses on compliance and regulatory matters, including anti-corruption, unfair competition, anti-monopoly, anti-fraud representations, anti-fraud and economic sanction areas.

Michelle has extensive experience in handling international transactions in a wide spectrum of practice areas across China, the USA and EU countries. With her long term, on-the-ground experience of doing business both within and outside China, she provides practical advice to clients on complex legal issues. Michelle often assumes the role of external general counsel for various clients on strategic development and compliance issues.

Prior to joining McDermott Will & Emery, Michelle was a Principal at Baker & McKenzie Shanghai from 2005 to 2015. She has also held various roles at Baker & McKenzie including Managing Partner of the Taipei office from 1989 till 2002. She served as the Chief Legal Officer/Vice President of Semiconductor Manufacturing International (Shanghai) Corporation from 2002 till 2005; and was an International Attorney for McDonald's Corporation, headquartered in Illinois from 1986 till 1989.

Michelle was named as one of the Top 30 Attorneys in China and one of the Top 100 Attorneys in the Asia Pacific region, by Asian Legal Business in 2004. She was listed as a leading lawyer in the life sciences sector in China by Chambers Asia Pacific in 2012, 2013, 2014 and 2015. Michelle was listed as a Corporate Investigation and Anti-bribery leading lawyer in China by Chambers Asia Pacific 2017. Michelle was ranked as a Corporate Investigation and Anti-bribery Spotlight Table of Foreign Legal Consultants China by Chambers Asia Pacific 2018.

She advises corporations across a number of sectors, including pharmaceuticals, medical devices, life sciences, health care, auto and parts, agriculture, food-related products, cosmetic, wine and spirits, hospitality, manufacturing, information technology (IT) and high tech. She has rich experience in handling IP matters.

Michelle is a member of the Illinois State Bar Association. She has been lecturing at the renowned Tsing Hua University for its international EMBA programs for several years.



Dale C. Van Demark
Partner | Washington, DC



☎ +1 202 756 8177
🖨 +1 202 756 8087
✉ dcvandemark@mwe.com

Dale C. Van Demark advises clients in the health industry on strategic transactions and the evolution of health care delivery models. He has extensive experience in health system affiliations and joint venture transactions. Dale also provides counseling on the development of technology in health care delivery, with a particular emphasis on telemedicine. Dale has been at the forefront of advising clients with respect to the globalization of the US health care industry. He advises US and non-US enterprises with respect to the formation of cross-border affiliations and international patient programs. In addition to writing regularly on matters related to his practice, Dale has spoken at numerous conferences around the world on the globalization of health care.

He is also a member of our legal cannabis industry group. Our Cannabis Industry group is a multidisciplinary team of lawyers providing clients with regulatory, litigation, intellectual property, trade and tax services with respect to their investments and participation in the cannabis industry, all subject to the Firm's obligations under federal and state laws and bar licensure rules.

RESULTS

- Frequently serves as lead transaction counsel for leading academic medical centers in affiliations with and acquisitions of community health systems
- Frequently serves as lead transaction and general counsel for community health systems seeking affiliation and acquisition partners
- Recently served as lead transaction counsel for a health system in the acquisition of a licensed managed care company
- Recently advised a leading telemedicine company in the design and implementation of its core business strategy
- Recently advised a leading academic medical center on the establishment of an affiliation with a Gulf State health care provider for the development of specific service lines in-country
- Recently advised a leading academic medical center on the establishment of an affiliation with an Asian industrial enterprise for the purpose of developing Asian hospitals



RECOGNITION

- Nightingale's Healthcare News 2009, Outstanding Hospital Lawyers

COMMUNITY

- Ripple Effect Images, board of directors
- Children's Health Fund, advisory council
- Patients Beyond Borders, advisory board
- American Health Lawyers Association, Business Law and Governance Section, Strategic Activities, former vice chair

CREDENTIALS

Education

Pace University School of Law, JD, cum laude, 1997

State University of New York – Purchase, BA, cum laude, 1994

Admissions

District of Columbia

New York



Emmanuelle Trombe

Partner | Paris



☎ +33 1 81 69 15 35

🖨 +33 1 81 69 15 15

✉ etrombe@mwe.com

Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerings, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities.

Emmanuelle Trombe is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is recommended for her expertise in the pharmaceutical, health care, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded.

RESULTS

- Represented Innate Pharma on its global co-development and commercialization agreement with AstraZeneca for IPH2201, a novel antibody in Phase II development for the treatment of cancer
- Represented Servier in connection with its strategic partnership with Intarcia Therapeutics. The transaction is one of the largest biotechnology partnership agreements outside the United States
- Represented Pierre Fabre on its collaboration and licensing agreement with Array Biopharma for the development and commercialization of two novel oncology products, Binimetinib and Encorafenib
- Represented DBV Technologies on its US\$281.5 million offering on NASDAQ
- Represented DBV on its collaboration agreement with Nestlé Health Science for the development and commercialization of a novel diagnostic test for pediatric milk allergy
- Represented Arterial Remodeling Technologies (ART), a French medtech developing an active bioabsorbable stent for the treatment of coronary disease, on its structured sale to the Japanese group Terumo Corporation

RECOGNITION

- Chambers Europe 2014 – 2019, Band 1, Pharma/Life Sciences (France): Emmanuelle is recommended for



her expertise in “commercial, corporate and regulatory matters in the industry of healthcare and medical devices.” She was described as: “very knowledgeable in pharma, bio-technology and licensing agreements. She is also very business-oriented.”

- The Legal 500 EMEA 2019, Healthcare and Life Sciences-France
- The Best Lawyers in France 2020, Biotechnology and Life Sciences Practice

COMMUNITY

- Médecins sans Frontières, regularly provides contractual advice to this international humanitarian medical association

CREDENTIALS

Education

École Supérieure de Commerce de Paris (ESCP)

University of Paris II Panthéon-Assas, LLM (Maîtrise), Tax and Commercial Law

Complutense University of Madrid, Master AMSEC

Admissions

Paris

Languages

English

French

Spanish

Italian



Byron S. Kalogerou

Partner | Boston



+1 617 535 4441

+1 617 535 3800

bkalogerou@mwe.com

Byron S. Kalogerou is the founder of the Firm's Life Science Industry Group and the senior attorney in the Boston Corporate Practice. He focuses his practice on domestic and cross-border mergers and acquisitions, finance, and joint ventures and alliances. He has substantial on-the-ground experience structuring mergers, acquisitions, divestitures and joint ventures on six continents. Byron has extensive industry background in the life science, industrial and manufacturing sectors. He also acts as outside general counsel to a number of companies.

Byron spent 17 years in-house, where he served in various general counsel roles at Tyco International, including as general counsel of its fire and security and telecom businesses and as general counsel of its international legal department, a function he created. Byron led many of Tyco's largest acquisitions, including the \$12 billion acquisition of AMP Inc. and the \$850 million purchase of AT&T Submarine Systems, and handled hundreds of middle-market deals around the globe. Byron also handled Tyco's initial foray into medical devices and led many of the deals that formed Covidien, now part of Medtronic.

Byron returned to law firm life 14 years ago with a desire to bring his keen sense of the "voice of the customer" to drive predictability, value and efficiency into the deal process. Byron is a pioneer in the use of legal project management and co-chair of the American Bar Association (ABA) Committee on Mergers and Acquisitions' Task Force on Legal Project Management. He is co-editor of the ABA Guidebook "Using Legal Project Management in Merger & Acquisition Transactions", now in its second edition. Byron also created the first-of-its-kind web-based collaborative deal management portal, which the Firm adopted and embraced as the M&A Gateway. He is also one of the Firm's primary contacts with the Association of Corporate Counsel.

Byron is a member of our legal cannabis industry group. Our Cannabis Industry group is a multidisciplinary team of lawyers providing clients with regulatory, litigation, intellectual property, trade and tax services with respect to their investments and participation in the cannabis industry, all subject to the Firm's obligations under federal and state laws and bar licensure rules.

RESULTS



- Represented Straumann AG, a global leader in tooth replacement solutions, in its acquisition of ClearCorrect, LLC, a leading manufacturer of clear aligners, for \$150 million.
- Represented Anvil, LLC, a leading North American manufacturer and supplier of products that connect, hang and support piping systems, in various acquisitions, including Flexhead Industries, Sprinkflex, Basic-PSA and Megawatt Machine.
- Represented Take 5 Media Group, a leading consumer information aggregation and advertising company, in the sale of its business to Advantage Solutions, a leading North American provider of business solutions to consumer goods manufacturers and retailers.
- Represented Covidien in its first equity acquisition in China of Changzhou Kangdi Medical Stapler Co., Ltd., a manufacturer of surgical stapler products
- Represented Rogers Corporation (NYSE: ROG), a global technology leader in specialty materials and components, in its \$157 million acquisition of Arlon, a global provider of high-frequency circuit materials and engineered silicones
- Represented Dimension Data, a global infrastructure solution (IS) provider and an NTT Group company, in its acquisition of Nexus IS, Inc., a \$471 million information technology (IT) solutions provider

RECOGNITION

- The Legal 500 United States 2012 to 2018
- Acritas Stars 2019, listed among independently rated lawyers
- LMG Life Sciences, Life Science Star 2016, 2018

COMMUNITY

- American Bar Association, Committee on Mergers and Acquisitions, co-chair, Task Force on Legal Project Management

CREDENTIALS

Education

Vermont Law School, JD, 1986

Harvard Business School, Advanced Management Program Certificate, 2001

Dartmouth College, BA, 1983

Phillips Exeter Academy, 1979

Admissions



Massachusetts



Dr. Stephan Rau

Partner | Munich



+49 89 12712 322

+49 89 12712 117

srau@mwe.com

Dr. Stephan Rau focuses his practice on mergers and acquisitions (M&A) transactions and regulatory advice in the health and life science sector. He is the head of the Firm's Health Law Practice Group in Europe.

In 2004, Stephan was adviser on the foundation of the first German corporate medical center. Since then he has represented numerous investors, health care service providers, pharmaceutical and medtech companies, as well as governmental entities in M&A transactions, outsourcing projects, and licensing and reimbursement proceedings.

Stephan speaks regularly at health care and life sciences industry as well as legal expert conferences, both at an international and national level. He is the author of numerous publications on German corporate law, health care and life sciences regulation.

For many years Stephan has consistently been ranked Tier 1 attorney for Health in Germany by Chambers Europe and "Elite Leading Lawyer" for Health and Life Sciences by Legal 500 Germany. JUVE lists Stephan as a frequently recommended lawyer for Corporate, M&A and Private Equity and a leading advisor for health. LMG Life Sciences Europe has repeatedly listed Stephan as a "Life Sciences Star" for his outstanding work in the industry.

RESULTS

- Advising on investments in the clinical lab, renal care, hospital, pharma, medical device, biotech, food and online pharmacy businesses
- Structuring various outsourcing projects, such as joint ventures between one of the largest medical schools in Europe and a large public hospital carrier leading to the establishment of the largest European clinical lab
- Challenging market entry barriers to dialysis service providers under the German system of determination of need of the statutory health insurance system
- Advising on disease management agreements with statutory health insurance funds
- Challenging one of the largest public tenders for pharmaceuticals by the largest German public payer
- Providing advice in connection with compulsory early benefit assessments for new pharmaceutical



products and related price negotiations under the Pharmaceuticals Market Reorganization Act (Arzneimittelmarkt-Neuordnungsgesetz (AMNOG)) proceedings

RECOGNITION

- Handelsblatt/Best Lawyers™ 2020 Germany: Leading Lawyer for Mergers and Acquisitions Law and Pharmaceuticals Law
- Leaders League's 2019 guide, Innovation, Technology & Patents, "Excellent" in the Health, pharma & biotechnology category
- The Best Lawyers in Germany 2019, Mergers & Acquisitions
- Chambers Europe 2019, Leading Individual, Band 1 for Healthcare in Germany
- Expert Guides; Best of the Best 2018: Regulatory, Financing & Transactional, Germany
- JUVE Handbook, frequently recommended lawyer for Corporate, M&A and Private Equity, and distinguished advisor for Health Services
- The Legal 500 2019, Leading Individual for Healthcare and Life Sciences
- The Legal 500 2017, Recommended Individual for Corporate M&A
- LMG Life Sciences, Life Science Star

COMMUNITY

- German-American Lawyers' Association
- German Association of Corporate Law
- International Bar Association, Health and Life Sciences Law Committee, Co-Chair
- Member of the advisory board of the Medical Law Institute (IMR) of the Bucerius Law School, Hamburg

CREDENTIALS

Education

Humboldt University of Berlin, Dr. jur. (PhD), 2003

Higher Court of Appeal, Berlin, Second State Exam, 1998

University of Heidelberg, First State Exam, 1996

University of Paris-Dauphine, Maîtrise en Économie Appliquée, 1994

London School of Economics and Political Science, Master of Science in Government, 1993

IHK Wiesbaden, interpreter and translator for Russian, 1990

Admissions



Germany

Courts / Agencies

All Courts and Courts of Appeal in Germany

Languages

English

German

French

Russian



Sarah Chapin Columbia

Partner | Boston



☎ +1 617 535 4074

🖨 +1 617 535 3800

✉ scolumbia@mwe.com

Sarah Chapin Columbia helps clients with matters related to intellectual property litigation, including patent, trademark, copyright and trade secrets. She is the former head of McDermott's Intellectual Property Practice and also serves on the Management Committee.

Sarah is a Fellow in the American College of Trial Lawyers. Over the last nine years, she has led 13 patent infringement and invalidity trials (eight jury trials, five bench trials) across several jurisdictions, including the federal courts in Massachusetts, Florida, Delaware, California and Texas.

Sarah also counsels clients on overall intellectual property strategy and positioning, including litigation avoidance. She provides legal services across several industries, including semiconductor, pharma/biotech, internet, hardware and software, medical device and manufacturing companies.

Sarah is a member of the faculty of the Munich Intellectual Property Law Center, where each year she teaches a two-day course focused on US patent litigation.

RESULTS

- Lead counsel for Amgen in a patent infringement action and jury trials involving breakthrough biologic therapy for the treatment of high LDL cholesterol (Amgen v. Sanofi, et al., (D. Delaware))
- Lead counsel for Amgen in a patent infringement action involving breakthrough biologic therapy for the treatment of atopic dermatitis and asthma (Amgen v. Sanofi and Regeneron (C.D. California))
- Lead counsel for BlackBerry in a patent infringement litigation and jury trial involving smart phone signaling (MTel v. BlackBerry, (N.D. Texas))
- Lead counsel for Seikagaku Corporation and Zimmer, Inc., in patent litigation, injunction hearings and jury trial involving a pharmaceutical device and treatment (Genzyme Corp. v. Seikagaku Corp., et al., (D. Massachusetts))
- Lead counsel for BlackBerry in a patent infringement litigation and jury trial involving three patents related to smartphone technology (NXP B.V. v. BlackBerry, (M.D. Florida))



- Lead counsel for Siemens Corporation in patent litigation involving product lifecycle management software and water filtration (Sky Technologies, LLC v. Siemens, (D. Massachusetts)) (Veolia Water Solutions & Technologies Support v. Siemens Industry, Inc., (D. North Carolina))
- Lead counsel for BlackBerry in a patent infringement litigation and jury trial involving three patents covering 3G wireless communications technology (Innovative Sonic, Ltd. v. BlackBerry et al., (N.D. Texas))
- Represented Akamai in two separate patent litigations involving internet content delivery and traffic management technology (Akamai Technologies, Inc. v. Speedera Networks, Inc., (D. Massachusetts)) (Akamai Technologies, Inc. v. Limelight Networks, Inc., (D. Massachusetts))
- Represented CIBA Vision Corporation in patent infringement litigation involving contact lenses (Johnson & Johnson Vision Care, Inc. v. CIBA Vision Corporation (M.D. Florida))
- Lead counsel for Citrix in a patent case accusing Citrix' Go-to-Meeting and Go-to-Webinar products (Pixion v. Citrix (N.D. California))
- Lead counsel in patent litigation involving process for ultra violet grafting on non-woven polymer films (Crane & Co. v. Hollingsworth & Vose Corp. (D. Massachusetts))
- Lead counsel for Furukawa Electric North America and its subsidiary, OFS Fitel, in patent infringement litigation involving optical fiber products and methods for manufacturing them (Furukawa Electric North America, Inc. v. Yangtze Fibre & Cable Company, Ltd. (D. Massachusetts))
- Lead counsel for MKS in three cases in the fields of mass flow controllers and monometers (Brooks Instruments v. MKS Instruments (E.D. Texas (two cases) and D. Massachusetts))
- Lead counsel for Teradyne Diagnostics and Teradyne, Inc. in patent litigation involving diesel engine diagnostic test equipment (Teradyne Diagnostic Solutions, Ltd. v. Mission Valley Ford Truck Sales, Inc. (E.D. Michigan); Mission Valley Ford Truck Sales, Inc. v. Teradyne, Inc. (N.D. California))

RECOGNITION

- [American College of Trial Lawyers 2016](#), 2016 Inductee
- Chambers USA 2008 to 2018 (Band 1)
- The Legal 500 2010 to 2018
- The Best Lawyers in America 2008 to 2019, Litigation – Intellectual Property, Litigation – Patent
- National Law Journal, 2015 [Litigation Trailblazer](#)
- Top 250 Women in IP 2017, Managing IP – IP Stars
- Law360, 2014 [Influential Woman in Intellectual Property Law](#)
- Managing Intellectual Property 2015 Massachusetts IP Litigator of the Year
- IAM Patent 1000 – The World's Leading Patent Practitioners 2013 to 2017
- Managing Intellectual Property, IP Stars 2013 to 2019
- Benchmark Litigation 2012 to 2019
- The Am Law Litigation Daily [Litigators of the Week](#), 2017



- LMG Life Sciences, Life Science Star, 2018

COMMUNITY

- Boston Bar Foundation, trustee
- Wesleyan University, President's Council

CREDENTIALS

Education

Harvard Law School, JD, magna cum laude, 1987

John F. Kennedy School of Government – Harvard University, MPP, 1987

Wesleyan University, BA, 1982

Admissions

Massachusetts

Courts / Agencies

Supreme Court of the United States

US Court of Appeals for the Federal Circuit

US Court of Appeals for the First Circuit

US Court of Appeals for the Second Circuit

US Court of Appeals for the Ninth Circuit